Move Over Mounjaro. Eli Lilly Has Another Blockbuster Opportunity in the Making, and No One Is Talking About It.
Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has ...
ARKG: Eyeing Favorable Macro 2025 Turns, Encouraging Momentum Trends
Financial writer recommends buying ARK Genomic Revolution ETF (ARKG) for potential growth in 2025. Explore more here.
Got $5,000? 2 Top Healthcare Stocks to Buy in 2025 and Hold Forever.
Vertex's lineup will look transformed in five years, and the company should continue performing well beyond that time. It's ...
Eli Lilly plans to expand its pipeline to address obesity-related conditions in India, says top executive
US-based pharmaceutical giant Eli Lilly is focusing on weight loss medications like Mounjaro (tirzepatide), which has proven ...
Prediction: 3 Stocks That'll Be Worth More Than Berkshire Hathaway 5 Years From Now
With that as the backdrop, here's a closer look at three names that could be worth more than Berkshire Hathaway just five ...
FiercePharma11h
Bristol Myers, Pfizer tout new standards of care in colorectal cancer subtypes
Old drugs from Bristol Myers Squibb and Pfizer have delivered what the companies and researchers believe could establish them ...
Pfizer succeeds in late-stage trial for colorectal cancer therapy
Pfizer (NYSE:PFE) announced Saturday that its colorectal cancer therapy Braftovi, as part of a combination regimen, reduced tumor size (confirmed objective response rate) in a late-stage trial with a ...